TY  - JOUR
AU  - Cowan, Juthaporn
AU  - Na, Il-Kang
AU  - Gladiator, André
AU  - Kamieniak, Marta
AU  - Mustafa, S Shahzad
TI  - Patient-reported outcomes with subcutaneous immunoglobulin in secondary immunodeficiency.
JO  - Frontiers in immunology
VL  - 16
SN  - 1664-3224
CY  - Lausanne
PB  - Frontiers Media
M1  - DKFZ-2025-00726
SP  - 1528414
PY  - 2025
AB  - Subcutaneous (SCIG) and intravenous immunoglobulin (IVIG) replacement are both used to prevent infections in patients with secondary immunodeficiency (SID). Compared with IVIG, SCIG has fewer systemic side effects and, additionally, facilitates home-based treatment. Shared decision-making practice should include discussion of aspects such as patient preference as well as the associated risks and benefits of treatment. We review the available evidence for the use of SCIG treatment in patients with SID, focusing on patient-reported outcomes (PROs). In most studies, there were improvements to health-related quality of life with SCIG treatment, compared with before initiating SCIG without prior IVIG treatment, or after switching to SCIG from IVIG treatment, or a no-SCIG/IVIG cohort. Treatment satisfaction with SCIG was similar between patients with SID and primary immunodeficiency disease. Patient preference and perception assessments highlighted the benefits of SCIG compared with IVIG, such as ease of use and administration, convenience, and time-effectiveness. In addition, many patients self-administered SCIG at home. Such aspects may be of specific benefit to patients with SID and hematological malignancy by reducing the risk of infection exposure in clinical settings. PRO data may be useful during shared decision-making discussions with patients with SID.
KW  - Humans
KW  - Patient Reported Outcome Measures
KW  - Immunologic Deficiency Syndromes: drug therapy
KW  - Immunologic Deficiency Syndromes: therapy
KW  - Immunologic Deficiency Syndromes: immunology
KW  - Immunoglobulins, Intravenous: administration & dosage
KW  - Immunoglobulins, Intravenous: therapeutic use
KW  - Quality of Life
KW  - Injections, Subcutaneous
KW  - Immunoglobulins: administration & dosage
KW  - Treatment Outcome
KW  - Infusions, Subcutaneous
KW  - health-related quality of life (Other)
KW  - hematological malignancy (Other)
KW  - patient preference (Other)
KW  - patient-reported outcomes (Other)
KW  - secondary immunodeficiency (Other)
KW  - shared decision-making (Other)
KW  - subcutaneous immunoglobulin (Other)
KW  - treatment satisfaction (Other)
KW  - Immunoglobulins, Intravenous (NLM Chemicals)
KW  - Immunoglobulins (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40181959
C2  - pmc:PMC11967276
DO  - DOI:10.3389/fimmu.2025.1528414
UR  - https://inrepo02.dkfz.de/record/300273
ER  -